Unknown

Dataset Information

0

Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.


ABSTRACT: We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK signaling between untreated and sorafenib-treated HCC cell lines were investigated using real-time polymerase chain reaction array. Western blot and real-time PCR further evaluated the expression of c-Jun. Pathological specimens from 50 patients with advanced HCC were collected to measure p-c-Jun expression. Sorafenib-resistant HCC cells demonstrated greater levels of basal c-Jun mRNA and protein compared with sorafenib-sensitive HCC cells. Sorafenib activated p-c-Jun in a dose- and time-dependent manner in PLC/PRF/5 and MHCC97H cell lines. Decreased expression levels of 6 genes after sorafenib treatment suggested a robust inhibitory impact of sorafenib on MAPK signaling in HCC cells. c-Jun and p-c-Jun expression levels were inversely correlated with the efficacy of sorafenib; a high expression level of p-c-Jun was associated with resistance to sorafenib and poor overall survival in patients with clinical HCC. p-c-Jun may act as a biomarker for predicting responses of sorafenib treatment, thus advocating targeting of JNK/c-Jun signaling as an optimal therapeutic strategy in a subset of HCC.

SUBMITTER: Chen W 

PROVIDER: S-EPMC4786823 | biostudies-other | 2016 Mar

REPOSITORIES: biostudies-other

altmetric image

Publications

Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.

Chen Wei W   Xiao Weikai W   Zhang Kunsong K   Yin Xiaoyu X   Lai Jiaming J   Liang Lijian L   Chen Dong D  

Scientific reports 20160311


We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK signaling between untreated and sorafenib-treated HCC cell lines were investigated using real-time polymerase chain reaction array. Western blot and real-time PCR further evaluated the expression of c-J  ...[more]

Similar Datasets

| S-EPMC8917761 | biostudies-literature
| S-EPMC4918283 | biostudies-literature
2010-07-20 | E-GEOD-15366 | biostudies-arrayexpress
2010-07-20 | GSE15366 | GEO
| S-EPMC7475472 | biostudies-literature
| S-EPMC3388555 | biostudies-literature
| S-EPMC5835851 | biostudies-literature
| S-EPMC9641807 | biostudies-literature
| S-EPMC8154901 | biostudies-literature
| S-EPMC10888718 | biostudies-literature